Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: A Phase I Multiple Myeloma Research Consortium study

British Journal of Haematology

Volumn 158, Issue 4, 2012, Pages 472-480

  Jakubowiak, Andrzej J ^a,i   Richardson, Paul G ^b   Zimmerman, Todd ^c   Alsina, Melissa ^d   Kaufman, Jonathan L ^e   Kandarpa, Malathi ^a   Kraftson, Stephanie ^a,j   Ross, Charles W ^f   Harvey, Colleen ^a   Hideshima, Teru ^b   Sportelli, Peter ^g   Poradosu, Enrique ^g   Gardner, Lesa ^g   Giusti, Kathy ^h   Anderson, Kenneth C ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g AKEBIA THERAPEUTICS   (United States)

^h Multiple Myeloma Research Consortium   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j MICHIGAN STATE UNIVERSITY   (United States)

more..

Author keywords

Akt; Dexamethasone; Lenalidomide; Perifosine; Relapsed multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; PERIFOSINE; PROTEIN KINASE B; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BEDTIME DOSAGE; BLOATING; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL RESEARCH; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MENTAL INSTABILITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84864322405     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09173.x     Document Type: Article

References (30)

1. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 102, 1115-1123.
2. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San, M.J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132.
3. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
4. Hideshima, T., Nakamura, N., Chauhan, D. & Anderson, K.C. (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20, 5991-6000.
5. Hideshima, T., Bergsagel, P.L., Kuehl, W.M. & Anderson, K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607-618.
6. Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N.C., Chauhan, D., Richardson, P.G. & Anderson, K.C. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107, 4053-4062.
7. Jakubowiak, A., Zimmerman, T., Alsina, M., Richardson, P., Kaufman, J., Kendall, T., Brozo, C., McAllister, A., Leister, C., Hideshima, T., Sportelli, P., Gardner, L., Birch, R., Henderson, I.C., Giusti, K. & Anderson, K. (2007) A Multiple Myeloma Research Consortium (MMRC) multicenter Phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM): updated results. Blood (ASH Annual Meeting Abstracts), 110, Abstract 1169.
8. Jakubowiak, A., Richardson, P.G., Zimmerman, T., Alsina, M., Kaufman, J., Harvey, C., Brozo, C., Kendall, T., McAllister, A., Hideshima, T., Sportelli, P., Gardner, L., Anderson, K. & Giusti, K. (2008) Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 112, Abstract 3691.
9. Knop, S., Gerecke, C., Liebisch, P., Topp, M.S., Platzbecker, U., Sezer, O., Vollmuth, C., Falk, K., Glasmacher, A., Maeder, U., Einsele, H. & Bargou, R.C. (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood, 113, 4137-4143.
10. Kropff, M., Bisping, G., Schuck, E., Liebisch, P., Lang, N., Hentrich, M., Dechow, T., Kroger, N., Salwender, H., Metzner, B., Sezer, O., Engelhardt, M., Wolf, H.H., Einsele, H., Volpert, S., Heinecke, A., Berdel, W.E. & Kienast, J. (2007) Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. British Journal of Haematology, 138, 330-337.
11. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
12. Kumar, S., Blade, J., Crowley, J., Goldschmidt, H., Hoering, A., Jagannath, S., Lahuerta, J.J., Laubach, J., Moreau, P., Morgan, G., Orlowski, R.Z., Palumbo, A., Richardson, P.G., San Miguel, J., Sezer, O., Siegel, D., Sonneveld, P., Szymonifka, J., Rajkumar, S.V. & Durie, B.G. (2009) Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Blood (ASH Annual Meeting Abstracts), 114, Abstract 2878.
13. Laubach, J.P., Mahindra, A., Mitsiades, C.S., Schlossman, R.L., Munshi, N.C., Ghobrial, I.M., Carreau, N., Hideshima, T., Anderson, K.C. & Richardson, P.G. (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia, 23, 2222-2232.
14. National Cancer Institute. (2006) National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0.
15. Orlowski, R.Z., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., San, M.J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H.J., Suvorov, A.N., Zhuang, S.H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W. & Harousseau, J.L. (2007) Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology, 25, 3892-3901.
16. Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., Avonto, I., Musto, P., Cascavilla, N., Bruno, B. & Boccadoro, M. (2008) Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Annals of Oncology, 19, 1160-1165.
17. Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le, G.S., Richardson, P., Munshi, N.C., Stirling, D.I., Antin, J.H. & Anderson, K.C. (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 104, 4188-4193.
18. Rajkumar, S.V., Fonseca, R., Vesole, D., Jacobus, S., Greipp, P.R., Weiss, M. & Katz, M. (2010a) A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for non-Responders.
19. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010b) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, 11, 29-37.
20. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
21. Richardson, P.G., Mitsiades, C., Schlossman, R., Munshi, N. & Anderson, K. (2007a) New drugs for myeloma. Oncologist, 12, 664-689.
22. Richardson, P.G., Lonial, S., Jakubowiak, A., Krishnan, A., Wolf, J., Densmore, J., Singhal, S., Ghobrial, I., Stephenson, J., Mehta, J., Colson, K., Francis, D., Kendall, T., Obadike, N., Sullivan, K., Martin, J., Hideshima, T., Lai, L., Sportelli, P., Gardner, L., Birch, R., Henderson, I.C. & Anderson, K. (2007b) Multi-center Phase ll study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma: promising activity as combination therapy with manageable toxicity. Blood (ASH Annual Meeting Abstracts), 110, Abstract 1164.
23. Richardson, P., Wolf, J., Jakubowiak, A., Zonder, J., Lonial, S., Irwin, D.H., Densmore, J., Krishnan, A., Raje, N., Bar, M., Allerton, J., Schlossman, R., Ghobrial, I., Munshi, N., Martin, T., Laubach, J., Colson, K., Dean, S., Tocco, D., Steinfield, E., Kendall, T., O'Riley, K., Hideshima, T., Sportelli, P., Gardner, L. & Anderson, K. (2008) Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood (ASH Annual Meeting Abstracts), 112, Abstract 870.
24. Richardson, P.G., Wolf, J., Jakubowiak, A., Zonder, J., Lonial, S., Irwin, D., Densmore, J., Krishnan, A., Raje, N., Bar, M., Martin, T., Schlossman, R., Ghobrial, I.M., Munshi, N., Laubach, J., Allerton, J., Hideshima, T., Colson, K., Poradosu, E., Gardner, L., Sportelli, P. & Anderson, K.C. (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter Phase I/II trial. Journal of Clinical Oncology, 29, 4243-4249.
25. Schey, S.A., Morgan, G.J., Ramasamy, K., Hazel, B., Ladon, D., Corderoy, S., Jenner, M., Phekoo, K., Boyd, K. & Davies, F.E. (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a Phase I/II study. British Journal of Haematology, 150, 326-333.
26. Shi, Y., Yan, H., Frost, P., Gera, J. & Lichtenstein, A. (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Molecular Cancer Therapeutics, 4, 1533-1540.
27. Siegel, D., Weber, D.M., Mitsiades, C.S., Dimopoulos, M.A., Harousseau, J.-L., Rizvi, S., Howe, J., Reiser, D., Byrne, C., Anderson, K.C. & Richardson, P. (2009) Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a Phase I study. Blood (ASH Annual Meeting Abstracts), 114, Abstract 305.
28. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133-2142.
29. World Medical Association (2009) World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. World Medical Association, Ferney-Voltaire, France.
30. Zollinger, A., Stuhmer, T., Chatterjee, M., Gattenlohner, S., Haralambieva, E., Muller-Hermelink, H.K., Andrulis, M., Greiner, A., Wesemeier, C., Rath, J.C., Einsele, H. & Bargou, R.C. (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood, 112, 3403-3411.